Kinnate Biopharma

US-based Kinnate Biopharma Inc., (NASDAQ: KNTE), a company dedicated to the development of small-molecule cancer drugs, has announced significant corporate restructuring due to financial stress. This includes a reduction of 70% of its workforce, leaving the company with only 28 employees. Pipeline Program AdjustmentsAs part of the restructuring, three pipeline…